Corvus Pharmaceuticals, Inc. (CRVS) Stock Price & Analysis
Corvus Pharmaceuticals, Inc. (CRVS) fell 4.46% to USD 13.07 as of July 25, 2026 at 04:20 UTC, according to Nexqual real-time market data.
CRVS last closed at USD 13.68; the session ranged USD 13.04–13.88 on volume of 955,808 shares. Market capitalization is $1.10B, with a 52-week range of USD 3.96–26.95 (NGM). Source: Nexqual, July 25, 2026 at 04:20 UTC.
Key Statistics (as of July 25, 2026 at 04:20 UTC)
| Price | USD 13.07 |
|---|---|
| Change | ▼ 4.46% (down) |
| Previous Close | USD 13.68 |
| Open | USD 13.75 |
| Day Range | USD 13.04 – 13.88 |
| 52-Week Range | USD 3.96 – 26.95 |
| Volume | 955,808 shares |
| Market Cap | $1.10B |
| Exchange | NGM |
Technical Analysis (CRVS)
Nexqual's technical model rates CRVS "NEUTRAL" based on 3 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 04:20 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 43.37 (neutral) |
| vs SMA50 | Below (USD 13.26) |
| MACD | 0.1 (positive) |
Analyst Ratings (CRVS)
Wall Street analysts rate CRVS "None" based on 6 analysts, with a mean price target of USD 33.33 (range USD 27–42), per Nexqual as of July 25, 2026 at 04:20 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 33.33 |
| High Target | USD 42 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (CRVS)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.17 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.15 ▲ beat |
| 2025-12-31 | USD -0.15 vs est -0.13 ▼ miss |
| 2025-09-30 | USD -0.12 vs est -0.14 ▲ beat |
| 2025-06-30 | USD -0.13 vs est -0.12 ▼ miss |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Financials & Fundamentals (CRVS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -30.46% |
| Debt / Equity | 0.35 |
| Current Ratio | 19.81 |
| Total Cash | $236.71M |
| Total Debt | $834,000 |
| Free Cash Flow | $-22.57M |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Financial Health Score (CRVS)
Nexqual rates Corvus Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $237M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$35M |
| Efficiency | Critical — ROE -30%, ROA -19.2% |
Ownership (CRVS)
| Insider Ownership | +3.51% |
|---|---|
| Institutional Ownership | +85.57% |
| Shares Outstanding | 84.09M |
| Float | 72.76M |
| Short % of Float | +25.44% |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Leadership (CRVS)
Corvus Pharmaceuticals, Inc. is led by Richard A. Miller (age 74), Co-Founder, President, CEO & Chairman of the Board, per Nexqual as of July 25, 2026 at 04:20 UTC.
| Co-Founder, President, CEO & Chairman of the Board | Richard A. Miller (age 74) |
|---|---|
| Co-Founder & Independent Director | Peter A. Thompson FACP (age 65) |
| Chief Financial Officer | Leiv Lea (age 71) |
| Senior Vice President of Pharmaceutical Development | William Benton Jones (age 59) |
Major Backers & Investors (CRVS)
Notable institutional backers of Corvus Pharmaceuticals, Inc. include Orbimed Advisors LLC., Adams Street Partners, LLC, Price (T.Rowe) Associates Inc, according to Nexqual as of July 25, 2026 at 04:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 8.52% |
| Adams Street Partners, LLC | 3.9% |
| Price (T.Rowe) Associates Inc | 3.47% |
| Vivo Capital, LLC | 3.34% |
| Morgan Stanley | 2.97% |
| Deep Track Capital, Lp | 2.96% |
| Wellington Management | 2.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.16% |
| State Street | 7.71% |
| Vanguard Group | 7.61% |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
From Corvus Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
- The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
- It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer.
- It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CYPH | Cypherpunk Technologies Inc. | USD 0.62 | ▼ 7.44% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
| EDSA | Edesa Biotech, Inc. | USD 5.25 | ▼ 7.57% |
| PTGX | Protagonist Therapeutics, Inc. | USD 136.11 | ▲ 0.49% |
| ACIU | AC Immune SA | USD 2.23 | ▼ 1.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:20 UTC. This page is informational and not investment advice.